Lexicon Pharmaceuticals (LXRX) Announces Earnings Results

Share on StockTwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.12, MarketWatch Earnings reports. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $13.33 million. During the same period last year, the business posted ($0.27) EPS. The business’s revenue was down 49.7% compared to the same quarter last year.

Shares of LXRX opened at $7.86 on Thursday. The stock has a market capitalization of $759.48 million, a PE ratio of -6.19 and a beta of 0.70. Lexicon Pharmaceuticals has a one year low of $4.26 and a one year high of $13.97.

Several institutional investors and hedge funds have recently modified their holdings of LXRX. Clearbridge Investments LLC grew its stake in shares of Lexicon Pharmaceuticals by 974,268.4% in the 3rd quarter. Clearbridge Investments LLC now owns 1,295,910 shares of the biopharmaceutical company’s stock valued at $13,827,000 after buying an additional 1,295,777 shares during the period. D. E. Shaw & Co. Inc. grew its stake in shares of Lexicon Pharmaceuticals by 181.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock valued at $1,783,000 after buying an additional 173,096 shares during the period. Norges Bank acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $1,005,000. First Trust Advisors LP acquired a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at about $1,525,000. Finally, Candriam Luxembourg S.C.A. grew its stake in shares of Lexicon Pharmaceuticals by 36.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 509,000 shares of the biopharmaceutical company’s stock valued at $5,431,000 after buying an additional 137,000 shares during the period. Institutional investors own 99.34% of the company’s stock.

A number of brokerages have weighed in on LXRX. BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 5th. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. Gabelli downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. Citigroup restated a “buy” rating and issued a $14.00 target price on shares of Lexicon Pharmaceuticals in a research note on Tuesday, January 22nd. They noted that the move was a valuation call. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $20.38.

TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals (LXRX) Announces Earnings Results” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/4220171/lexicon-pharmaceuticals-lxrx-announces-earnings-results.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: NASDAQ Stock Market Explained

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Buying: ANNALY CAP MGMT/SH  Director Acquires 30,000 Shares of Stock
Insider Buying: ANNALY CAP MGMT/SH Director Acquires 30,000 Shares of Stock
Hastings Group  Receives New Coverage from Analysts at Panmure Gordon
Hastings Group Receives New Coverage from Analysts at Panmure Gordon
Asbury Automotive Group  Upgraded to “Buy” by Zacks Investment Research
Asbury Automotive Group Upgraded to “Buy” by Zacks Investment Research
$1.27 Earnings Per Share Expected for Tenneco Inc  This Quarter
$1.27 Earnings Per Share Expected for Tenneco Inc This Quarter
ALLETE Inc  Shares Bought by Dimensional Fund Advisors LP
ALLETE Inc Shares Bought by Dimensional Fund Advisors LP
Financial Gravity Companies Inc. Takes $163,000 Position in Facebook, Inc.
Financial Gravity Companies Inc. Takes $163,000 Position in Facebook, Inc.


© 2006-2019 Ticker Report